Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:54:38 EDT Tue 19 May 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:NBIX - NEUROCRINE BIOSCIENCES INC - https://WWW.NEUROCRINE.COM
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NBIX - Q0.1149.35·154.051.1154.36-2.85-1.81,386.4212,75219,901156.59  156.88  153.27162.39  117.8419:35:38May 1815 min RT 2¢

Recent Trades - Last 10 of 19901
Time ETExPriceChangeVolume
19:35:38Q152.84-4.371
19:11:45Q151.49-5.721
18:43:23Q153.0746-4.13541
18:26:55Q152.84-4.3715
18:26:39Q151.49-5.7215
16:28:33Q154.33-2.881
16:28:09Q154.33-2.887
16:26:41Q151.48-5.732
16:26:41Q151.48-5.731
16:26:41Q152.15-5.061

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-05-18 16:05U:NBIXNews ReleaseNeurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA(TM) (valbenazine) Capsules
2026-05-18 08:46U:NBIXNews ReleaseNeurocrine Biosciences Completes Acquisition of Soleno Therapeutics
2026-05-06 08:30U:NBIXNews ReleaseNeurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY(TM) (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia
2026-05-05 16:01U:NBIXNews ReleaseNeurocrine Biosciences Reports First-Quarter 2026 Financial Results
2026-05-05 09:00U:NBIXNews ReleaseNeurocrine Biosciences to Present at the Bank of America Health Care Conference 2026
2026-05-04 08:30U:NBIXNews ReleaseNeurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment
2026-05-04 07:30U:NBIXNews ReleaseNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist
2026-05-01 16:05U:NBIXNews ReleaseNeurocrine Biosciences Presents New Two-Year CRENESSITY(TM) (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia
2026-04-29 16:05U:NBIXNews ReleaseNeurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale
2026-04-22 16:05U:NBIXNews ReleaseNeurocrine Biosciences Presents New Two-Year CRENESSITY(TM) (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia
2026-04-14 16:01U:NBIXNews ReleaseNeurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results
2026-04-14 08:30U:NBIXNews ReleaseNeurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA(TM) (valbenazine) Capsules Compared to AUSTEDO XR
2026-04-06 07:00U:NBIXNews ReleaseNeurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
2026-03-26 08:30U:NBIXNews ReleaseNeurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings
2026-03-17 16:05U:NBIXNews ReleaseNeurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer
2026-03-10 16:01U:NBIXNews ReleaseNeurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum
2026-02-24 16:01U:NBIXNews ReleaseNeurocrine Biosciences to Present at Upcoming Investor Conferences in March
2026-02-11 16:01U:NBIXNews ReleaseNeurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026
2026-01-26 08:30U:NBIXNews ReleaseNeurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia
2026-01-21 16:01U:NBIXNews ReleaseNeurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results